Sponsor: Chugai Pharmaceuticals
Sponsor Study ID: SAL101JG
Study Title: Phase 1 Dose Escalation Study for a Trispecific Antibody (SAIL66), Targeting Solid Tumors Expressing CLDN-6 and CD3/CD137+ T-cells
CTO #: 103834
NCT Number: NCT05735366
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Anus, Bladder, Bones and Joints, Breast, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit
Study Objectives: Incidence, nature, and severity of adverse events graded according to NCI Common Terminology CTCAE v5.0, with severity of CRS and ICANS determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria. Incidence, nature, and severity of adverse events graded according to NCI CTCAE v5.0, with severity of CRS and ICANS determined according to the ASTCT Consensus Grading Criteria.